Company page

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, trading under the ticker ABUS, is a public company based in the United States with a market capitalization of approximately $898.8 million. The company focuses on developing innovative therapies for the treatment of viral diseases, particularly hepatitis B. Arbutus aims to advance its pipeline of drug candidates to address unmet medical needs in this area.